Stock Track | ALI HEALTH Soars 5.96% Intraday on Exclusive Launch of Groundbreaking Drug Bemeijing®

Stock Track01-14

ALI HEALTH (00241) saw its stock price surge by 5.96% during the intraday session on Wednesday, driven by the exclusive launch of Bemeijing®, a milestone drug for infantile hemangioma, on its platform.

The improved new drug Timolol Maleate Gel, branded as Bemeijing®, is the world's first and only topical gel approved for treating proliferative superficial infantile hemangioma. This achievement marks a significant leap for China in the global pharmaceutical market. The drug's value was further validated by the issuance of the first overseas drug price certificate, establishing a benchmark for China's original research drugs internationally.

This development underscores ALI HEALTH's strategic positioning in the pharmaceutical sector and its potential for growth, as the platform continues to innovate and expand its offerings in the healthcare market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1181344305?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181344305","market":"hk","top_or_hot":-1,"title":"Stock Track | ALI HEALTH Soars 5.96% Intraday on Exclusive Launch of Groundbreaking Drug Bemeijing®","media":"Stock Track","content":"<p>ALI HEALTH (00241) saw its stock price surge by 5.96% during the intraday session on Wednesday, driven by the exclusive launch of Bemeijing®, a milestone drug for infantile hemangioma, on its platform.</p><p>The improved new drug Timolol Maleate Gel, branded as Bemeijing®, is the world's first and only topical gel approved for treating proliferative superficial infantile hemangioma. This achievement marks a significant leap for China in the global pharmaceutical market. The drug's value was further validated by the issuance of the first overseas drug price certificate, establishing a benchmark for China's original research drugs internationally.</p><p>This development underscores ALI HEALTH's strategic positioning in the pharmaceutical sector and its potential for growth, as the platform continues to innovate and expand its offerings in the healthcare market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ALI HEALTH Soars 5.96% Intraday on Exclusive Launch of Groundbreaking Drug Bemeijing®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ALI HEALTH Soars 5.96% Intraday on Exclusive Launch of Groundbreaking Drug Bemeijing®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-14 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ALI HEALTH (00241) saw its stock price surge by 5.96% during the intraday session on Wednesday, driven by the exclusive launch of Bemeijing®, a milestone drug for infantile hemangioma, on its platform.</p><p>The improved new drug Timolol Maleate Gel, branded as Bemeijing®, is the world's first and only topical gel approved for treating proliferative superficial infantile hemangioma. This achievement marks a significant leap for China in the global pharmaceutical market. The drug's value was further validated by the issuance of the first overseas drug price certificate, establishing a benchmark for China's original research drugs internationally.</p><p>This development underscores ALI HEALTH's strategic positioning in the pharmaceutical sector and its potential for growth, as the platform continues to innovate and expand its offerings in the healthcare market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00241","symbol_name":"阿里健康","start_time":0,"source_url":"","article_id":"1181344305","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181344305","pubTimestamp":1768356745,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ALI HEALTH (00241) saw its stock price surge by 5.96% during the intraday session on Wednesday, driven by the exclusive launch of Bemeijing®, a milestone drug for infantile hemangioma, on its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00241":"阿里健康"},"translate_title":"股票赛道|独家推出突破性药物倍美净阿里健康盘中暴涨5.96%®","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"ALI HEALTH (00241) saw its stock price surge by 5.96% during the intraday session on Wednesday, driven by the exclusive launch of Bemeijing®, a milestone drug for infantile hemangioma, on its platform.The improved new drug Timolol Maleate Gel, branded as Bemeijing®, is the world's first and only topical gel approved for treating proliferative superficial infantile hemangioma. This achievement marks a significant leap for China in the global pharmaceutical market. The drug's value was further validated by the issuance of the first overseas drug price certificate, establishing a benchmark for China's original research drugs internationally.This development underscores ALI HEALTH's strategic positioning in the pharmaceutical sector and its potential for growth, as the platform continues to innovate and expand its offerings in the healthcare market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1181344305","isCrawlerRequest":true}